Related Experiment Video
Updated: Jun 24, 2026
08:03
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Novel targeted agents for lung cancer
1Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA 98104, USA. howard.west@swedish.org
Clinical Lung Cancer
|April 14, 2009
Summary
Novel targeted therapies show promise for advanced non-small-cell lung cancer (NSCLC). Emerging treatments, including immunotherapies and novel agents, offer encouraging results in early trials, potentially improving patient outcomes.
Area of Science:
- Oncology
- Pharmacology
Background:
- Improving survival in non-small-cell lung cancer (NSCLC) remains a challenge.
- Targeted therapies like EGFR inhibitors and angiogenesis inhibitors have improved treatment standards.
Purpose of the Study:
- To review current data and future directions for novel targeted therapies in advanced NSCLC.
- To highlight emerging strategies with encouraging early clinical trial results.
Main Methods:
- Review of current clinical trial data for novel targeted therapies.
- Analysis of immunotherapies, vaccines, and molecularly targeted agents.
- Focus on agents targeting MUC1, MAGE-A3, EGFR, insulin-like growth factor receptor, and heat-shock protein.
Main Results:
- Several novel targeted therapies are emerging with encouraging results in early clinical trials for advanced NSCLC.
- Immunotherapies targeting MUC1, MAGE-A3, and EGFR show early clinical benefits.
- Belagenpumatucel-L (vaccine) and talactoferrin alfa show potential for improved outcomes through immune activation.
Conclusions:
- Novel targeted therapies, including immunotherapies and agents inhibiting growth factor or heat-shock pathways, are advancing for advanced NSCLC.
- These approaches demonstrate activity in early trials and warrant further investigation.
- Future research directions focus on these promising novel strategies for NSCLC treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...